DC16

Background: Nestlé Research has performed a range of pre-clinical and clinical studies with NAD precursors including a comparative clinical metabolomics study of the NAD metabolome in blood cells of healthy adults, and demonstrated health efficacy of different dietary NAD precursors that are tissue-specific and involve complex metabolic cross-talks. In our research program on the nutritional management of sarcopenia, we have demonstrated that NAD levels are low in skeletal muscle of sarcopenic patients and that trigonelline (a novel NAD precursor) associates with muscle health in humans7.

Objectives: (1) Characterize cell type specific uptake and changes of the NAD metabolome in liver, kidney, muscle, and blood cells treated with different dietary NAD precursors (NR, NMN, NAM, trigonelline, tryptophane) (2) Characterization of NAD precursor metabolic fluxes in cells using isotope tracing (HILIC-HRMS). (3) Modelling of metabolic fluxes in the NAD metabolome using cellular data and pre-existing clinical data, and prediction of synergies between NAD precursors and interaction with physiopathology. (4) Validation of combinations of NAD precursors on age-related health benefits using existing lifespan and healthspan assays in C. elegans